Further validation of Novacyt’s expertise in developing assays for clinical applications Novacyt Signs Assay Development Contract for Diagnosis of Respiratory Infections with GenePOC Paris, France and Camberley, UK – 22 March 2018 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, today announces its molecular testing division, Primerdesign, has entered into
Visit PageYear: 2018
NOVACYT REVENUES FULL YEAR 2017
Novacyt revenues full year 2017 PR ENG Delivers record revenue growth of 35% China sales exceed expectations Successfully completed dual-listing on AIM
Visit PageFOR THE THIRD YEAR RUNNING NOVACYT IS PLACED IN THE TECHNOLOGY FAST 500 EMEA AWARDS
Novacyt Fast 500 PR Paris, France and Cambridge, UK – 2 January 2018 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, today announces it has been ranked 135 in Deloitte’s Technology Fast 500™ EMEA. The awards rank 500 Technology, Media and Telecommunications companies with the highest rate of growth in
Visit Page